Hans V. Hogerzeil

Hans V. Hogerzeil

Auto-generated profile, based on publicly available information

Hans V. Hogerzeil

Global Health Unit, Department of Health Sciences, University Medical Centre Groningen, University of Groningen, P.O. Box 196 9700 AD Groningen, Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
DMDaniela Moye-Holz
Daniela Moye-Holz
MEMargaret Ewen
Margaret Ewen
ADAnahi Dreser
Anahi Dreser
SBSergio Bautista-Arredondo
Sergio Bautista-Arredondo
RSRene Soria-Saucedo
Rene Soria-Saucedo
HHHans V. Hogerzeil
Hans V. Hogerzeil
Background: More alternatives have become available for the diagnosis and treatment of cancer in low- and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region. Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO’s Strategic Fund. Results: Of the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%, respectively. In the public sector, medicines covered by the public health insurance “People’s Health Insurance” were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region. Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization’s 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.

26 August 2018 in Global Public Health
Verified
Journal Article
Closed access
KPKatrina Perehudoff
Katrina Perehudoff
NANikita Alexandrov
Nikita Alexandrov
HHHans V. Hogerzeil
Hans V. Hogerzeil
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in 194 health systems. We present a follow-up report of eight indicators for access to medicines to serve as a reference point for progress towards SDG Target 3.8 on essential medicines. Data for these eight indicators in 2015 were collected and compared with the 2008 report. Between 2008 and 2015 we observed increased numbers of constitutions recognising access to medicines (7–13 countries), countries with a national medicine policy (118–122) and with a national list of essential medicines (78–107). Public spending on pharmaceuticals decreased or rose modestly in most of the 44 countries. Median availability of a basket of lowest-priced generics increased in the public (63%–70% n = 9 countries) and private (84%–92% n = 10) sectors. Median child immunisation rates remained constant for measles (around 90%) and improved for three doses of diphtheria-tetanus-pertussis (79%–86%). These eight indicators are useful and feasible, but should be further strengthened and expanded. Future monitoring exercises should use these indicators to screen progress and guide national governments’ action to ensure universal access to essential medicines as part of the right to health.

9 January 2019 in Journal of Public Health Policy
Verified
Journal Article
Open access
PDF file
HHHans V. Hogerzeil
Hans V. Hogerzeil
SRSterre Recourt
Sterre Recourt
Diabetes mellitus is rapidly becoming one of the major diseases affecting people’s health globally. Over half of 100 million diabetes patients who need insulin to survive, especially in low- and...

1 September 2020 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DMDaniela Moye-Holz
Daniela Moye-Holz
ADAnahi Dreser
Anahi Dreser
Jitse P Van DijkJitse P Van Dijk
Jitse P Van Dijk
SRSijmen Reijneveld
Sijmen Reijneveld
HHHans V. Hogerzeil
Hans V. Hogerzeil

21 May 2025 in The Lancet
Verified
Journal Article
Closed access
VWVeronika J Wirtz
Veronika J Wirtz
HHHans V Hogerzeil
Hans V Hogerzeil
AGAndrew L Gray
Andrew L Gray